Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer,

Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules,
  and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen,
                   Express Scripts, and Forest Laboratories

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 20, 2014

NEW YORK, March 20, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Pfizer Inc.
(NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB),
Express Scripts Inc. (NASDAQ: ESRX), and Forest Laboratories Inc. (NYSE: FRX).
Private wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:



On March 14, 2014, Pfizer Inc. (Pfizer), along with the Bristol-Myers Squibb
Company, reported that the U.S. Food and Drug Administration (FDA) has
provided an approval on a Supplemental New Drug Application (sNDA) for Eliquis
(apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead
to pulmonary embolism (PE), in patients who have undergone hip or knee
replacement surgery. Commenting on the release, Steven J. Romano, M.D., Senior
Vice President and Medicines Development Group Head, stated, "As the number of
hip and knee replacement surgeries performed in the U.S. continues to
increase, the risk of DVT following these surgeries remains a concern for
physicians. Eliquis provides patients and physicians with a new treatment
option that offers twice daily oral dosing and no routine coagulation testing,
and is broadly accessible through hospitals and managed health care
formularies." The full analyst notes on Pfizer Inc. are available to download
free of charge at:



On March 11, 2014, Johnson & Johnson announced that Dominic Caruso, Vice
President, Finance and CFO, along with Louise Mehrotra, Vice President,
Investor Relations, will host the Company's conference call for investors on
April 15, 2014, at 8:30 a.m. ET. According to the release, Caruso and Mehrotra
will review the Company's Q1 2014 results. Additionally, the Company stated
that interested parties may access a live webcast of the conference call,
which is optimized for mobile streaming on iOS devices, on the Johnson &
Johnson Investor Relations website as well as a podcast replay (available
approximately two hours after the conference call). The full analyst notes on
Johnson & Johnson are available to download free of charge at:



On March 17, 2014, Biogen Idec Inc.'s (Biogen) stock went up by 4.04%, at
$345.60 per share. Over the past one-month trading period, Biogen's stock went
up by 5.27%, outperforming the Nasdaq Composite which went up by 0.85% during
the same one-month trading period. The full analyst notes on Biogen Idec Inc.
are available to download free of charge at:



On March 12, 2014, Express Scripts Inc. (Express Scripts) announced that
according to its most current and comprehensive analysis of Attention Deficit
Hyperactivity Disorder (ADHD) medication, the number of Americans who use
medication to treat ADHD rose 36% in five years, reaching a total of more than
4.8 million privately insured individuals in 2012. According to Express
Scripts, the TurningAttentiontoADHD report shows that during the
five-year study the greatest increase of medication usage was among adults
with the largest usage increase of 85%, seen in women ages 26-34. Commenting
on the release, David Muzina, M.D., Company Vice President of Specialist
Practice, stated, "While generally safe for the majority of the population of
patients, ADHD medications require judicious prescribing. Our clinical
programs and model of specialized pharmacy practice, which includes
neuroscience and behavioral health, provide an important safety net for
patients who may be struggling with side effects from ADHD drugs, as well as
additional mental disorders that can complicate their care." The full analyst
notes on Express Scripts Inc. are available to download free of charge at:



On March 17, 2014, Forest Laboratories Inc.'s (Forest Laboratories) stock
declined by 0.27%, closing at $95.25 per share. For the past six-month trading
period, Forest Laboratories' shares reflected a significant increase of
113.57%, compared to the Dow Jones Industrial Average which went up by 4.62%,
during the same trading period. The full analyst notes on Forest Laboratories
Inc. are available to download free of charge at:


We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.




  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oForanyurgentconcernsorinquiries, please contact us at compliance
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.